Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Treasury Shares: 2016-2025

Historic Treasury Shares for Akebia Therapeutics (AKBA) over the last 4 years, with Sep 2025 value amounting to $6.2 million.

  • Akebia Therapeutics' Treasury Shares rose 50.60% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 50.60%. This contributed to the annual value of $4.1 million for FY2024, which is 23.01% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Treasury Shares of $6.2 million as of Q3 2025, which was down 3.13% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Treasury Shares registered a high of $7.9 million during Q2 2023, and its lowest value of $3.3 million during Q4 2023.
  • Over the past 3 years, Akebia Therapeutics' median Treasury Shares value was $4.2 million (recorded in 2024), while the average stood at $5.1 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first plummeted by 45.19% in 2024, then skyrocketed by 67.86% in 2025.
  • Akebia Therapeutics' Treasury Shares (Quarterly) stood at $4.6 million in 2021, then increased by 24.59% to $5.7 million in 2022, then crashed by 41.14% to $3.3 million in 2023, then grew by 23.01% to $4.1 million in 2024, then spiked by 50.60% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $6.4 million for Q2 2025, and $6.7 million during Q1 2025.